compstatin control peptide Search Results


compstatin control peptide  (MuseChem Chemicals)
N/A
Compstatin control peptide（Cat No.:P000246）is a synthetic analog of Compstatin, a well-known cyclic peptide inhibitor of complement component C3, but designed with sequence modifications that eliminate inhibitory activity. While it maintains similar physicochemical properties, it does
   Buy from Supplier
compstatin control peptide acetate  (TargetMol)
N/A
   Buy from Supplier
compstatin control peptide  (Tocris)
90
Tocris compstatin control peptide
Inhibition of properdin protects endothelial cells from heme-induced complement activation. (A,B) Complement activation on heme-treated endothelial cells is alternative-pathway dependent. HUVECs were stimulated with M199 media or 100 μM hemin, washed and incubated with NHS or Factor B-depleted serum (FB-dpl) (15% final), in the presence or absence of Cp20 (50 μM) or EDTA (20 mM). 54 nM Factor B (FB) was used to restore Factor B-depleted serum activity. (C) Anti-properdin MoAb protects heme-treated HUVECs from C3 fragment deposition. HUVECs were stimulated with 100 μM hemin (or M199), NHS (33% final) and one of the following reagents at the indicated final concentrations: Cp20 (50 μM), <t>Compstatin</t> control peptide (“Cp20 Control,” 50 μM), anti-properdin MoAb 6E11A4 (80 nM), IgG1 isotype control (80 nM), eculizumab (53 nM or 80 nM) or SALO (5 μM). (A–C) C3 deposition (GMFI) was determined as described in “Materials and Methods” and “Fold difference” was calculated by dividing GMFI of each group by GMFI of NHS alone group. (A) is a combination of four independent experiments (each with duplicates), (B,C) are representative of four and two independent experiments, respectively, with duplicates. The data was analyzed by one-way ANOVA with Tukey's multiple comparison test. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, p > 0.05 ns. Statistical analysis between NHS+heme group and each inhibitor group is shown in (C) .
Compstatin Control Peptide, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compstatin+control+peptide/Compstatin+control+peptide/pmc07387411-59-0-3
Average 90 stars, based on 1 article reviews
compstatin control peptide - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
control peptide  (Biosynth Carbosynth)
86
Biosynth Carbosynth control peptide
Inhibition of properdin protects endothelial cells from heme-induced complement activation. (A,B) Complement activation on heme-treated endothelial cells is alternative-pathway dependent. HUVECs were stimulated with M199 media or 100 μM hemin, washed and incubated with NHS or Factor B-depleted serum (FB-dpl) (15% final), in the presence or absence of Cp20 (50 μM) or EDTA (20 mM). 54 nM Factor B (FB) was used to restore Factor B-depleted serum activity. (C) Anti-properdin MoAb protects heme-treated HUVECs from C3 fragment deposition. HUVECs were stimulated with 100 μM hemin (or M199), NHS (33% final) and one of the following reagents at the indicated final concentrations: Cp20 (50 μM), <t>Compstatin</t> control peptide (“Cp20 Control,” 50 μM), anti-properdin MoAb 6E11A4 (80 nM), IgG1 isotype control (80 nM), eculizumab (53 nM or 80 nM) or SALO (5 μM). (A–C) C3 deposition (GMFI) was determined as described in “Materials and Methods” and “Fold difference” was calculated by dividing GMFI of each group by GMFI of NHS alone group. (A) is a combination of four independent experiments (each with duplicates), (B,C) are representative of four and two independent experiments, respectively, with duplicates. The data was analyzed by one-way ANOVA with Tukey's multiple comparison test. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, p > 0.05 ns. Statistical analysis between NHS+heme group and each inhibitor group is shown in (C) .
Control Peptide, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compstatin+control+peptide/Compstatin+control+peptide/pm26505972-55-7-13
Average 86 stars, based on 1 article reviews
control peptide - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
compstatin control peptide  (BOC Sciences)
N/A
Compstatin control peptide is a kind of control peptide for compstatin. It is a complement inhibitor.
   Buy from Supplier
compstatin control peptide tfa  (TargetMol)
N/A
   Buy from Supplier
compstatin control peptide tfa salt  (Aladdin Scientific Corporation)
N/A
   Buy from Supplier

Image Search Results


Inhibition of properdin protects endothelial cells from heme-induced complement activation. (A,B) Complement activation on heme-treated endothelial cells is alternative-pathway dependent. HUVECs were stimulated with M199 media or 100 μM hemin, washed and incubated with NHS or Factor B-depleted serum (FB-dpl) (15% final), in the presence or absence of Cp20 (50 μM) or EDTA (20 mM). 54 nM Factor B (FB) was used to restore Factor B-depleted serum activity. (C) Anti-properdin MoAb protects heme-treated HUVECs from C3 fragment deposition. HUVECs were stimulated with 100 μM hemin (or M199), NHS (33% final) and one of the following reagents at the indicated final concentrations: Cp20 (50 μM), Compstatin control peptide (“Cp20 Control,” 50 μM), anti-properdin MoAb 6E11A4 (80 nM), IgG1 isotype control (80 nM), eculizumab (53 nM or 80 nM) or SALO (5 μM). (A–C) C3 deposition (GMFI) was determined as described in “Materials and Methods” and “Fold difference” was calculated by dividing GMFI of each group by GMFI of NHS alone group. (A) is a combination of four independent experiments (each with duplicates), (B,C) are representative of four and two independent experiments, respectively, with duplicates. The data was analyzed by one-way ANOVA with Tukey's multiple comparison test. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, p > 0.05 ns. Statistical analysis between NHS+heme group and each inhibitor group is shown in (C) .

Journal: Frontiers in Immunology

Article Title: Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation

doi: 10.3389/fimmu.2020.01460

Figure Lengend Snippet: Inhibition of properdin protects endothelial cells from heme-induced complement activation. (A,B) Complement activation on heme-treated endothelial cells is alternative-pathway dependent. HUVECs were stimulated with M199 media or 100 μM hemin, washed and incubated with NHS or Factor B-depleted serum (FB-dpl) (15% final), in the presence or absence of Cp20 (50 μM) or EDTA (20 mM). 54 nM Factor B (FB) was used to restore Factor B-depleted serum activity. (C) Anti-properdin MoAb protects heme-treated HUVECs from C3 fragment deposition. HUVECs were stimulated with 100 μM hemin (or M199), NHS (33% final) and one of the following reagents at the indicated final concentrations: Cp20 (50 μM), Compstatin control peptide (“Cp20 Control,” 50 μM), anti-properdin MoAb 6E11A4 (80 nM), IgG1 isotype control (80 nM), eculizumab (53 nM or 80 nM) or SALO (5 μM). (A–C) C3 deposition (GMFI) was determined as described in “Materials and Methods” and “Fold difference” was calculated by dividing GMFI of each group by GMFI of NHS alone group. (A) is a combination of four independent experiments (each with duplicates), (B,C) are representative of four and two independent experiments, respectively, with duplicates. The data was analyzed by one-way ANOVA with Tukey's multiple comparison test. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, p > 0.05 ns. Statistical analysis between NHS+heme group and each inhibitor group is shown in (C) .

Article Snippet: Compstatin control peptide (Tocris) was used as the control for Cp20.

Techniques: Inhibition, Activation Assay, Incubation, Activity Assay, Control, Comparison